In collaboration with our academic partner TRICALS, Amylyx Pharmaceuticals is conducting a Phase 3 trial to determine the safety and efficacy of their investigational drug ‘AMX0035’ for the treatment of ALS.

AMX0035

AMX0035 consists of a combination of two molecules: tauroursodeoxycholic acid (TUDCA) and sodium phenylbutyrate. Both were previously shown to be safe and well tolerated. The combination of the two drugs is believed to decrease nerve cell damage in people living with ALS.

All information on the study overview, key eligibility criteria and participating TRICALS centers can be found here at the TRICALS website.